Literature DB >> 29176656

Clinical trials: Treatment of HCV-infected patients with advanced kidney disease.

Marco Ladino1, David Roth2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29176656     DOI： 10.1038/nrneph.2017.161

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  8 in total

1.  Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function.

Authors:  Varun Saxena; Farrukh M Koraishy; Meghan E Sise; Joseph K Lim; Monica Schmidt; Raymond T Chung; Annmarie Liapakis; David R Nelson; Michael W Fried; Norah A Terrault
Journal:  Liver Int       Date:  2016-03-24       Impact factor: 5.828

2.  Mortality, Hospitalization, and Quality of Life among Patients with Hepatitis C Infection on Hemodialysis.

Authors:  David A Goodkin; Brian Bieber; Michel Jadoul; Paul Martin; Eiichiro Kanda; Ronald L Pisoni
Journal:  Clin J Am Soc Nephrol       Date:  2016-12-01       Impact factor: 8.237

3.  Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans.

Authors:  Miklos Z Molnar; Hazem M Alhourani; Barry M Wall; Jun L Lu; Elani Streja; Kamyar Kalantar-Zadeh; Csaba P Kovesdy
Journal:  Hepatology       Date:  2015-03-20       Impact factor: 17.425

4.  Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease.

Authors:  Paul J Pockros; K Rajender Reddy; Parvez S Mantry; Eric Cohen; Michael Bennett; Mark S Sulkowski; David E Bernstein; Daniel E Cohen; Nancy S Shulman; Deli Wang; Amit Khatri; Manal Abunimeh; Thomas Podsadecki; Eric Lawitz
Journal:  Gastroenterology       Date:  2016-03-11       Impact factor: 22.682

Review 5.  Hepatitis C Virus Infection in Chronic Kidney Disease.

Authors:  Marco Ladino; Fernando Pedraza; David Roth
Journal:  J Am Soc Nephrol       Date:  2016-04-19       Impact factor: 10.121

Review 6.  Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality?

Authors:  F Fabrizi; V Dixit; P Messa
Journal:  J Viral Hepat       Date:  2012-07-17       Impact factor: 3.728

7.  Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.

Authors:  Edward Gane; Eric Lawitz; David Pugatch; Georgios Papatheodoridis; Norbert Bräu; Ashley Brown; Stanislas Pol; Vincent Leroy; Marcello Persico; Christophe Moreno; Massimo Colombo; Eric M Yoshida; David R Nelson; Christine Collins; Yang Lei; Matthew Kosloski; Federico J Mensa
Journal:  N Engl J Med       Date:  2017-10-12       Impact factor: 91.245

8.  Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.

Authors:  David Roth; David R Nelson; Annette Bruchfeld; AnnMarie Liapakis; Marcelo Silva; Howard Monsour; Paul Martin; Stanislas Pol; Maria-Carlota Londoño; Tarek Hassanein; Philippe J Zamor; Eli Zuckerman; Shuyan Wan; Beth Jackson; Bach-Yen Nguyen; Michael Robertson; Eliav Barr; Janice Wahl; Wayne Greaves
Journal:  Lancet       Date:  2015-10-05       Impact factor: 202.731
  8 in total
  1 in total

1.  A Patient Decision Support Tool for Hepatitis C Virus and CKD Treatment.

Authors:  Nerissa George; AnnMarie Liapakis; Kevin M Korenblat; Tingting Li; David Roth; Jerry Yee; Kevin J Fowler; Lehman Howard; Jingxia Liu; Mary C Politi
Journal:  Kidney Med       Date:  2019-07-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.